Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

PURPOSE: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor with few treatment options. We designed a phase II randomized trial to determine the activity and tolerability of single-agent cediranib or sunitinib in patients with advanced metastatic ASPS. PATIENTS AND METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, James, Takebe, Naoko, Kummar, Shivaani, Razak, Albiruni, Chawla, Sant P., George, Suzanne, Patel, Shreyaskumar R., Keohan, Mary Louise, Movva, Sujana, O'Sullivan Coyne, Geraldine, Do, Khanh, Juwara, Lamin, Augustine, Brooke, Steinberg, Seth M., Kuhlmann, Laura, Ivy, S. Percy, Doroshow, James H., Chen, Alice P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068440/
https://www.ncbi.nlm.nih.gov/pubmed/36302173
http://dx.doi.org/10.1158/1078-0432.CCR-22-2145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068440/
https://www.ncbi.nlm.nih.gov/pubmed/36302173
http://dx.doi.org/10.1158/1078-0432.CCR-22-2145

Ejemplares similares